PMID- 35370654
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220405
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 13
DP  - 2022
TI  - Efficacy and Adverse Events of PD-1 Inhibitors in Patients With Advanced 
      Urothelial Carcinoma From a Real-World Experience.
PG  - 837499
LID - 10.3389/fphar.2022.837499 [doi]
LID - 837499
AB  - Background: Programmed death 1 (PD-1) inhibitors-tislelizumab, toripalimab, 
      camrelizumab, and sintilimab-are used for advanced urothelial carcinoma (UC) in 
      China. To date, the efficacy and adverse events (AEs) of these PD-1 inhibitors 
      have been poorly reported for advanced UC. Methods: We reviewed 118 patients 
      treated with PD-1 inhibitors for advanced UC from July 2019 to October 2021 at 
      Yantai Yuhuangding Hospital. Patient data were obtained from hospital records and 
      telephone follow-ups. The safety and efficacy of PD-1 inhibitors were assessed by 
      RESIST and Common Terminology Criteria for Adverse Events (version 4.0), 
      respectively. Results: During a median follow-up period of 6 months, 112 patients 
      (95%) experienced AEs; of these, 104 (88%) were grade 1-2 AEs, and 60 (51%) were 
      grade 3-4 AEs. The most common AE was anemia, and no patients died as a result of 
      treatment. A subanalysis according to treatment method (PD-1 inhibitor vs. PD-1 
      inhibitor plus chemotherapy) was performed. The incidence of grade 1-2 AEs was 
      not different between the groups (85% vs. 94%), but combination therapy 
      significantly increased grade 3-4 AEs (32% vs. 89%). Monotherapy and combination 
      therapy also did not differ with regard to immune-related AEs of grades 1-2 (13% 
      vs. 22%) or grades 3-4 (1% vs. 6%). In efficacy, complete response was not 
      observed, but 33 patients (28%) had partial response, 30 (25%) had stable 
      disease, and 47 had progressive disease (40%). The overall response and disease 
      control rates were 28% and 53%, respectively. The preliminary efficacy of disease 
      control was better with combination therapy versus monotherapy (78 vs. 43%). 
      Conclusion: PD-1 inhibitors show promising tolerance and efficacy in advanced UC. 
      PD-1 inhibitors combined with chemotherapy offered better disease control but had 
      more grade 3-4 AEs. The clinical use of combination therapy warrants caution.
CI  - Copyright (c) 2022 Sun, Wang, Liu, Wang, Zhang, Yao, Sun, Zhou, Lu and Wu.
FAU - Sun, Fengze
AU  - Sun F
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Wang, Dawei
AU  - Wang D
AD  - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Liu, Aina
AU  - Liu A
AD  - Department of Oncology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Wang, Tianqi
AU  - Wang T
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Zhang, Dongxu
AU  - Zhang D
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Yao, Huibao
AU  - Yao H
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Sun, Kai
AU  - Sun K
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
FAU - Zhou, Zhongbao
AU  - Zhou Z
AD  - Department of Urology, Beijing Tiantan Hospital, Capital Medical University, 
      Beijing, China.
FAU - Lu, Guoliang
AU  - Lu G
AD  - Department of Urology, Ruijin Hospital, Shanghai Jiaotong University School of 
      Medicine, Shanghai, China.
FAU - Wu, Jitao
AU  - Wu J
AD  - Department of Urology, Yantai Yuhuangding Hospital, Qingdao University, Yantai, 
      China.
LA  - eng
PT  - Journal Article
DEP - 20220318
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8971813
OTO - NOTNLM
OT  - adverse events
OT  - chemotherapy
OT  - efficacy
OT  - programmed death -1/programmed death ligand 1 (PD-1/PD-L1)
OT  - urothelial carcinoma
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/04/05 06:00
MHDA- 2022/04/05 06:01
PMCR- 2022/03/18
CRDT- 2022/04/04 05:27
PHST- 2021/12/16 00:00 [received]
PHST- 2022/01/17 00:00 [accepted]
PHST- 2022/04/04 05:27 [entrez]
PHST- 2022/04/05 06:00 [pubmed]
PHST- 2022/04/05 06:01 [medline]
PHST- 2022/03/18 00:00 [pmc-release]
AID - 837499 [pii]
AID - 10.3389/fphar.2022.837499 [doi]
PST - epublish
SO  - Front Pharmacol. 2022 Mar 18;13:837499. doi: 10.3389/fphar.2022.837499. 
      eCollection 2022.